Home › Research › Treatments
Blood Pressure Variability and Progression of Clinical Alzheimer Disease
de Heus RAA, Olde Rikkert MGM, Tully PJ, Lawlor BA, Claassen JAHR, NILVAD Study Group.. Hypertension (Dallas, Tex. : 1979), 2019-09-23
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Blood pressure variability (BPV) has been shown to have predictive value over blood pressure (BP) levels alone in stroke patients. We assessed whether BPV predicts cognitive and functional decline in Alzheimer disease, using data from a randomized trial (NILVAD [A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease]). Patients with mild-to-moderate Alzheimer disease were included if they had ≥3 office BP measurements available to determine visit-to-visit BPV. Day-to-day BPV was assessed using home BP measurements in a subsample. The variation independent of mean was used to calculate BPV. Outcomes were change in Alzheimer's Disease Assessment Scale-cognitive subscale-12 and Disability Assessment for Dementia after 1 and 1.5 years. A total of 460 patients aged 72.1 (SD=8.1) years, with mean BP of 134.0/75.1 (10.9/6.3) mm Hg were included. After 1 year, patients in the highest quartile of BPV had deteriorated more on Alzheimer's Disease Assessment Scale-cognitive subscale compared with patients in the lowest quartile (systolic: β, 2.24 [95% CI, 0.11-4.38], P =0.040; diastolic: β, 2.54 [95% CI, 0.33-4.75] P =0.024). This association was still present after 1.5 years (systolic: β, 2.86 [95% CI, 0.35-5.36], P =0.026; diastolic: β, 3.30 [95% CI, 0.67-5.93], P =0.014). There was no effect of visit-to-visit BPV on Disability Assessment for Dementia. Day-to-day BPV was available for 46 patients. Significant associations were observed between day-to-day BPV and deterioration on Alzheimer's Disease Assessment Scale-cognitive subscale (systolic: P =0.036) and Disability Assessment for Dementia (systolic: P =0.020; diastolic: P =0.007) after 1 year, but not after 1.5 years. All associations were adjusted for potential confounders, including intervention group. In conclusion, this post hoc analysis indicates that higher visit-to-visit and day-to-day BPV might be associated with progression of Alzheimer disease. Targeting BPV may be a future target to slow decline in patients with Alzheimer disease. Clinical Trial Registration URL: https://www.clinicaltrials.gov. Unique identifier: NCT02017340.
What this study adds
Evidence grade: High
This is a trial of 460 participants. Day-to-day blood pressure variability was also associated with deterioration on cognition and disability measures.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
de Heus, R. A. A., Olde Rikkert, M. G. M., Tully, P. J., Lawlor, B. A., Claassen, J. A. H. R., & NILVAD Study Group. (2019). Blood Pressure Variability and Progression of Clinical Alzheimer Disease. Hypertension (Dallas, Tex. : 1979). https://doi.org/10.1161/hypertensionaha.119.13664
Vancouver
de Heus RAA, Olde Rikkert MGM, Tully PJ, Lawlor BA, Claassen JAHR, NILVAD Study Group. Blood Pressure Variability and Progression of Clinical Alzheimer Disease. Hypertension (Dallas, Tex. : 1979). 2019. doi:10.1161/hypertensionaha.119.13664. PMID: 31542965.
BibTeX
@article{deheus2019-31542965,
author = {de Heus, R. A. A. and Olde Rikkert, M. G. M. and Tully, P. J. and Lawlor, B. A. and Claassen, J. A. H. R. and {NILVAD Study Group}},
title = {{Blood Pressure Variability and Progression of Clinical Alzheimer Disease}},
journal = {Hypertension (Dallas, Tex. : 1979)},
year = {2019},
doi = {10.1161/hypertensionaha.119.13664},
pmid = {31542965},
url = {https://doi.org/10.1161/hypertensionaha.119.13664}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- After 1 year, patients in the highest quartile of BPV had deteriorated more on Alzheimer's Disease Assessment Scale-cognitive subscale compared with patients in the lowest quartile (systolic: β, 2.24 [95% CI, 0.11-4.38], P =0.040; diastolic: β, 2.54 [95% CI, 0.33-4.75] P =0.024).
- Significant associations were observed between day-to-day BPV and deterioration on Alzheimer's Disease Assessment Scale-cognitive subscale (systolic: P =0.036) and Disability Assessment for Dementia (systolic: P =0.020; diastolic: P =0.007) after 1 year, but not after 1.5 years.
- In conclusion, this post hoc analysis indicates that higher visit-to-visit and day-to-day BPV might be associated with progression of Alzheimer disease.
Why it matters
Using data from 460 patients with mild-to-moderate Alzheimer disease in a randomized trial, this study found that patients in the highest quartile of blood pressure variability had greater cognitive deterioration on the ADAS-cog after 1 and 1.5 years than those in the lowest quartile. Day-to-day blood pressure variability was also associated with deterioration on cognition and disability measures.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designrandomized controlled trial
- Participants460
- Evidence strengthHigh
How this study scored 67/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 64 of the 96 points we could judge it on, which is 67 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Hypertension (Dallas, Tex. : 1979)) |
| Journal's citation record | 3 / 4 | Hypertension: journal h-index 369 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 2 / 4 | 460 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 4 / 7 | Cited 89 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 9.9 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 4 / 6 | Cited 8.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 31 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 1 / 3 | Radboud University Nijmegen: institution h-index 1,143 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31542965) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 64 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 64 of the 96 points we could judge it on is 67 out of 100. |
| Total | 67 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1161/hypertensionaha.119.13664
- PubMed: 31542965
- Original source →
- Free full text: ahajournals.org →
Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also in Treatments
196 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.